Compass Financial Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Compass Financial Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.9K	Buy	+300	New	+$24.7K	﹤0.01%	829

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return

Compass Financial Management's PBE Position: Q2 2026 in Review

Compass Financial Management opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q2 2026: 300 shares worth $26.9K. The stake represents ﹤0.01% of the portfolio and ranks #829 among its holdings.

100 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

Compass Financial Management held 300 shares of Invesco Biotechnology & Genome ETF worth $26.9K as of Q2 2026.
Invesco Biotechnology & Genome ETF was a new Compass Financial Management position in Q2 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Compass Financial Management's portfolio in Q2 2026, its #829 holding.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.